| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $92.9M | +7.0% |
| SG&A Expense | $30.7M | +13.7% |
| Operating Income | -$123.5M | -8.6% |
| Net Income | -$115.4M | -3.4% |
| EPS (Basic) | -$2.44 | -0.4% |
| EPS (Diluted) | -$2.44 | -0.4% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $30.6M | -3.8% |
| Short-term Investments | $171.1M | -34.0% |
| Current Assets | $204.4M | -30.7% |
| Total Assets | $220.5M | -27.7% |
| Current Liabilities | $21.7M | +13.0% |
| Total Liabilities | $25.1M | +30.5% |
| Stockholders' Equity | $195.4M | -31.6% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$83.7M | -0.2% |
| Capital Expenditures | $3.0M | +30.0% |
| Investing Cash Flow | $81.7M | +131.0% |
| Financing Cash Flow | $815K | -99.5% |
| Free Cash Flow | -$86.7M | -1.0% |